title: Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis.
authors.forename: Federico
authors.initials: F
authors.lastname: Alghisi
authors.forename: Paolo
authors.initials: P
authors.lastname: Palma
authors.forename: Enza
authors.initials: E
authors.lastname: Montemitro
authors.forename: Stefania
authors.initials: S
authors.lastname: Bernardi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pontrelli
authors.forename: Paolo
authors.initials: P
authors.lastname: Rossi
authors.forename: Vincenzina
authors.initials: V
authors.lastname: Lucidi
mesh_terms: D000276:Adjuvants, Immunologic; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000276:immunology*; D005260:Female; D006801:Humans; D007223:Infant; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control*; D008297:Male; D011136:Polysorbates; D013185:Squalene / Q000276:immunology; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D007252:Influenza Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D013185:Squalene